Adocia https://validator.w3.org/feed/docs/rss2.html AdoShell®, a non-fibrotic encapsulation system for human islet transplantation without immunosuppression, Oral Presentation, Dr Anne-Lise Gaffuri, 20th World Congress of the international pancreas and islet transplant association (IPITA 2025) AdoShell®, a non-fibrotic encapsulation system for human islet transplantation without immunosuppression, Oral Presentation, Dr Anne-Lise Gaffuri, 20th World Congress of the international pancreas and islet transplant association (IPITA 2025) Adoshell®: a permselective and non-fibrotic scaffold for human islet transplantation, Poster, Dr Clément Cocita, European islet study group 2025, Malmö, Sweden Adoshell®: a permselective and non-fibrotic scaffold for human islet transplantation, Poster, Dr Clément Cocita, European islet study group 2025, Malmö, Sweden Développement d’AdoGel®, un hydrogel injectable permettant une libération prolongée de semaglutide sur un mois, Short Oral Presentation, Dr Audrey Maréchal, Congrès annuel de la SFD 2025 Développement d’AdoGel®, un hydrogel injectable permettant une libération prolongée de semaglutide sur un mois, Short Oral Presentation, Dr Audrey Maréchal, Congrès annuel de la SFD 2025 AdoShell®, un nouveau biomatériau pour la transplantation d’ilots, Short Oral Presentation, Camille Gautier, Congrès annuel de la SFD 2025 AdoShell®, un nouveau biomatériau pour la transplantation d’ilots, Short Oral Presentation, Camille Gautier, Congrès annuel de la SFD 2025 AdOral®—A Versatile Platform for Improved Oral Peptide Absorption, Poster, Dr Martin Gaudier, 18th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2025), Amsterdam, Netherlands AdOral®—A Versatile Platform for Improved Oral Peptide Absorption, Poster, Dr Martin Gaudier, 18th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2025), Amsterdam, Netherlands AdoShell®, a non-fibrotic immunoprotective hydrogel shows efficient and sustained in vivo functionality for clinical use, Oral Presentation, Dr Anne-Lise Gaffuri, 18th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2025), Amsterdam, Netherlands AdoShell®, a non-fibrotic immunoprotective hydrogel shows efficient and sustained in vivo functionality for clinical use, Oral Presentation, Dr Anne-Lise Gaffuri, 18th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2025), Amsterdam, Netherlands AdoShell®, a non-fibrotic immunoprotective hydrogel containing human islets shows efficient and sustained in vivo functionality for clinical use, Oral Presentation, Dr Ouardane Jouannot, 14th EPITA Symposium, Pisa, Italy AdoShell®, a non-fibrotic immunoprotective hydrogel containing human islets shows efficient and sustained in vivo functionality for clinical use, Oral Presentation, Dr Ouardane Jouannot, 14th EPITA Symposium, Pisa, Italy ADO12, a non-fibrotic immunoprotective hydrogel containing human islets shows efficient and sustained in vivo functionality for clinical use, Oral Presentation, Dr Anne-Lise Gaffuri, 60th annual meeting, EASD 2024, Madrid, Spain ADO12, a non-fibrotic immunoprotective hydrogel containing human islets shows efficient and sustained in vivo functionality for clinical use, Oral Presentation, Dr Anne-Lise Gaffuri, 60th annual meeting, EASD 2024, Madrid, Spain Development of a once-a-month formulation of Semaglutide from an innovative injectable and biodegradable hydrogel, Short Oral Presentation, Dr Claire Mégret, 60th annual meeting, EASD 2024, Madrid, Spain Development of a once-a-month formulation of Semaglutide from an innovative injectable and biodegradable hydrogel, Short Oral Presentation, Dr Claire Mégret, 60th annual meeting, EASD 2024, Madrid, Spain Development of a once-a-month formulation of Semaglutide from an innovative injectable and biodegradable hydrogel, Poster, Dr Olivier Soula, 84th scientific Sessions, ADA 2024, Orlando, USA Development of a once-a-month formulation of Semaglutide from an innovative injectable and biodegradable hydrogel, Poster, Dr Olivier Soula, 84th scientific Sessions, ADA 2024, Orlando, USA AdOral ®—A Versatile Platform for Improved Oral Peptide Absorption, Poster, Dr Ouardane Jouannot, 84th scientific Sessions, ADA 2024, Orlando, USA AdOral ®—A Versatile Platform for Improved Oral Peptide Absorption, Poster, Dr Ouardane Jouannot, 84th scientific Sessions, ADA 2024, Orlando, USA AdoShell®, a non fibrotic, immunoprotective encapsulation system for human islets transplantation shows promising results for clinical application as a cure for people with Type 1 Diabetes, Poster, Dr Ouardane Jouannot, 84th scientific Sessions, ADA 2024, Orlando, USA AdoShell®, a non fibrotic, immunoprotective encapsulation system for human islets transplantation shows promising results for clinical application as a cure for people with Type 1 Diabetes, Poster, Dr Ouardane Jouannot, 84th scientific Sessions, ADA 2024, Orlando, USA AdoShell®, un nouveau biomatériau pour la transplantation d’ilots, Oral Presentation, Dr Rosy Eloy, Congrès annuel de la SFD 2024 AdoShell®, un nouveau biomatériau pour la transplantation d’ilots, Oral Presentation, Dr Rosy Eloy, Congrès annuel de la SFD 2024 ADO12, a new allogenic islet encapsulation device for islet transplantation without immunosuppression, Oral Presentation, Dr Anne-Lise Gaffuri, 59th annual meeting, EASD 2023, Hamburg, Germany How to deliver a therapeutic dose of encapsulated human islets? , Oral Presentation, Dr Rosy Eloy, IPITA-IXA-CTRMS Joint Congress 2023, San Diego, USA How to deliver a therapeutic dose of encapsulated human islets? , Oral Presentation, Dr Rosy Eloy, IPITA-IXA-CTRMS Joint Congress 2023, San Diego, USA ADO12, a new allogenic islet encapsulation device for islet transplantation without immunosuppression, Oral Presentation, Dr Anne-Lise Gaffuri, 59th annual meeting, EASD 2023, Hamburg, Germany AdoShell® Islets shows long-term in vitro and in vivo survival and functionality of encapsulated pancreatic islets, Oral Presentation, Dr Ouardane Jouannot, 83rd scientific Sessions, ADA 2023, San Diego, USA AdoShell® Islets shows long-term in vitro and in vivo survival and functionality of encapsulated pancreatic islets, Oral Presentation, Dr Ouardane Jouannot, 83rd scientific Sessions, ADA 2023, San Diego, USA Home Development toward clinical application of AdoShell®, an encapsulation system for pancreatic islet transplantation, Poster, June 5, 2026, 86th Scientific Sessions ADA 2026, New Orleans, USA Stable co-formulation of cagrilintide and semaglutide enabled by the BioChaperone® technology for multi-dose pen injectors, Poster, October 27, 2025, PODD 2025, Boston, USA Stable co-formulation of cagrilintide and semaglutide enabled by the BioChaperone® technology for multi-dose pen injectors, Poster, October 27, 2025, PODD 2025, Boston, USA Ultra-Rapid TDB0206 Injection (BioChaperone Lispro, BCLIS) Improves Postprandial And Daily Glucose Control Vs. Lispro (LIS) In Chinese People With Type 2 Diabetes (T2D), Poster, June 5, 2026, 86th Scientific Sessions ADA 2026, New Orleans, USA Ultra-Rapid TDB0206 Injection (BioChaperone Lispro, BCLIS) Improves Postprandial And Daily Glucose Control Vs. Lispro (LIS) In Chinese People With Type 2 Diabetes (T2D), Poster, June 5, 2026, 86th Scientific Sessions ADA 2026, New Orleans, USA AdoXLong platform applied to semaglutide for once-monthly administration, Poster, June 5, 2026, 86th Scientific Sessions ADA 2026, New Orleans, USA AdoXLong platform applied to semaglutide for once-monthly administration, Poster, June 5, 2026, 86th Scientific Sessions ADA 2026, New Orleans, USA 2026 ADOCIA publie ses résultats financiers du premier semestre 2026 et dresse un bilan de ses activités ADOCIA Reports First Half 2026 Financial Results and Provides a Business Update Protected: ADOCIA : Information relative au nombre d’actions et de droits de vote en date du 30 septembre 2026 Number of Shares and Voting Rights of ADOCIA as of September 30, 2026 Development toward clinical application of AdoShell®, an encapsulation system for pancreatic islet transplantation, Poster, June 5, 2026, 86th Scientific Sessions ADA 2026, New Orleans, USA ADOCIA annonce des présentations orales lors du congrès annuel de l’EASD et du congrès Breakthrough T1D Clinical & Research ADOCIA Announces Oral Presentations at EASD Annual Meeting and at Breakthrough T1D Clinical & Research Congress 2026